[1]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2005/267191,2005,A1Locationinpatent:Page/Pagecolumn5-6
[1]Patent:WO2008/131149,2008,A2.Locationinpatent:Page/Pagecolumn28-29
[1]CurrentPatentAssignee:Sandoz(in:Novartis);NOVARTISAG-EP2368874,2011,A1
[1]CurrentPatentAssignee:Sandoz(in:Novartis);NOVARTISAG-EP2368874,2011,A1
[1]CurrentPatentAssignee:Sandoz(in:Novartis);NOVARTISAG-EP2368874,2011,A1
Title: Saxagliptin: a novel antiparkinsonian approach.
Journal: Neuropharmacology 20150201
Title: Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Journal: International journal of clinical pharmacy 20130401
Title: Saxagliptin overview: special focus on safety and adverse effects.
Journal: Expert opinion on drug safety 20130101
Title: Development of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study.
Journal: Biomedical chromatography : BMC 20121201
Title: Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
Journal: Pharmacoepidemiology and drug safety 20121101
Title: Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Journal: Journal of clinical pharmacology 20121001
Title: Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20121001
Title: Recent advances in incretin-based therapies.
Journal: Clinical endocrinology 20121001
Title: Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Journal: Bioorganic & medicinal chemistry 20121001
Title: Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
Journal: Current medical research and opinion 20121001
Title: Linagliptin as add-on therapy for type 2 diabetes - an overview.
Journal: Drugs of today (Barcelona, Spain : 1998) 20121001
Title: GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
Journal: Current clinical pharmacology 20120801
Title: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Journal: Clinical pharmacokinetics 20120801
Title: Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
Journal: Bioanalysis 20120801
Title: Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
Journal: Primary care diabetes 20120701
Title: Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120701
Title: The incretin hormones: from scientific discovery to practical therapeutics.
Journal: Diabetologia 20120701
Title: Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
Journal: Clinical drug investigation 20120701
Title: Drug-induced hypoglycaemia in type 2 diabetes.
Journal: Expert opinion on drug safety 20120701
Title: Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
Journal: Diabetes, obesity & metabolism 20120601
Title: An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Journal: Current diabetes reviews 20120501
Title: Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Journal: Diabetes, obesity & metabolism 20120401
Title: DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Journal: Diabetes & metabolism 20120401
Title: Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Journal: Current medical research and opinion 20120401
Title: Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Journal: Diabetes technology & therapeutics 20120401
Title: Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Journal: Diabetes, obesity & metabolism 20120401
Title: Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120315
Title: Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
Journal: Diabetes/metabolism research and reviews 20120301
Title: Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Journal: Annals of medicine 20120301
Title: Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
Journal: Clinical drug investigation 20120301
Title: Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Journal: Expert opinion on drug metabolism & toxicology 20120301
Title: Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Journal: The Annals of pharmacotherapy 20120301
Title: Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
Journal: Minerva endocrinologica 20120301
Title: Pleiotropic effects of incretins.
Journal: Indian journal of endocrinology and metabolism 20120301
Title: Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Journal: Drugs 20120122
Title: The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.
Journal: Diabetes technology & therapeutics 20120101
Title: A review of gliptins in 2011.
Journal: Expert opinion on pharmacotherapy 20120101
Title: Metformin + saxagliptin for type 2 diabetes.
Journal: Expert opinion on pharmacotherapy 20120101
Title: DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Journal: Advances in therapy 20120101
Title: A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Journal: Journal of clinical pharmacology 20120101
Title: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Journal: Cardiovascular diabetology 20120101
Title: Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Journal: Cardiovascular diabetology 20120101
Title: A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
Journal: Pharmacoepidemiology and drug safety 20120101
Title: Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.
Journal: Diabetology & metabolic syndrome 20120101
Title: The influence of incretin mimetics on cardiovascular risk factors in diabetes.
Journal: ISRN endocrinology 20120101
Title: Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Journal: BMC pharmacology 20120101
Title: Uncovering undetected hypoglycemic events.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
Title: Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.
Journal: Experimental diabetes research 20120101
Title: Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.
Journal: ISRN endocrinology 20120101
Title: Red carpeting the newer antidiabetics.
Journal: Journal of pharmacology & pharmacotherapeutics 20120101
Title: The management of type 2 diabetic patients with hypoglycaemic agents.
Journal: ISRN endocrinology 20120101
Title: Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
Title: Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.
Journal: Revista da Associacao Medica Brasileira (1992) 20120101
Title: Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.
Journal: Swiss medical weekly 20120101
Title: Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin.
Journal: The Journal of organic chemistry 20111216
Title: Impact of diabetes on postinfarction heart failure and left ventricular remodeling.
Journal: Current heart failure reports 20111201
Title: Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Journal: International journal of clinical practice 20111201
Title: [Incretin-based therapy for treating patients with type 2 diabetes].
Journal: Orvosi hetilap 20111127
Title: Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
Journal: Diabetes, obesity & metabolism 20111101
Title: Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
Journal: Diabetes research and clinical practice 20111101
Title: Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
Journal: Clinical therapeutics 20111101
Title: The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Journal: American heart journal 20111101
Title: Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Journal: Current medical research and opinion 20111101
Title: [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Journal: Orvosi hetilap 20110911
Title: Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20110901
Title: Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.
Journal: Annales d'endocrinologie 20110901
Title: Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Journal: Recent patents on endocrine, metabolic & immune drug discovery 20110901
Title: Enhanced glycemic control with combination therapy for type 2 diabetes in primary care.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901
Title: Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
Journal: Journal of medicinal chemistry 20110825
Title: Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.
Journal: The American journal of cardiology 20110802
Title: Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.
Journal: Clinical therapeutics 20110801
Title: Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.
Journal: Southern medical journal 20110801
Title: Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.
Journal: Expert opinion on drug discovery 20110801
Title: Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Journal: Drugs 20110730
Title: Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Journal: Diabetes, obesity & metabolism 20110701
Title: Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Journal: Diabetes, obesity & metabolism 20110701
Title: Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Journal: British journal of clinical pharmacology 20110701
Title: Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Journal: Postgraduate medicine 20110701
Title: Health economic evaluation of dipeptidyl peptidase-4 inhibitors.
Journal: Indian journal of endocrinology and metabolism 20110701
Title: Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Journal: Diabetes, obesity & metabolism 20110601
Title: Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.
Journal: Diabetes, obesity & metabolism 20110601
Title: The many faces of the adamantyl group in drug design.
Journal: European journal of medicinal chemistry 20110601
Title: Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
Journal: Southern medical journal 20110601
Title: Recent diabetes issues affecting the primary care clinician.
Journal: Southern medical journal 20110601
Title: Enzymatic preparation of 5-hydroxy-L-proline, N-Cbz-5-hydroxy-L-proline, and N-Boc-5-hydroxy-L-proline from (α-N-protected)-L-ornithine using a transaminase or an amine oxidase.
Journal: Enzyme and microbial technology 20110506
Title: An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Journal: Contemporary clinical trials 20110501
Title: DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
Journal: Diabetes care 20110501
Title: Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Journal: Clinical therapeutics 20110501
Title: Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Journal: Clinical therapeutics 20110501
Title: Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501
Title: Pro-soft Val-boroPro: a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases.
Journal: Journal of medicinal chemistry 20110414
Title: Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
Journal: Diabetes, obesity & metabolism 20110401
Title: Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
Journal: Current medical research and opinion 20110401
Title: Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry.
Journal: Analytical and bioanalytical chemistry 20110401
Title: Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Journal: Clinical pharmacokinetics 20110401
Title: FDA's first active medical product surveillance eyes antidiabetic-MI link.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110401
Title: Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Journal: Diabetes & vascular disease research 20110401
Title: Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks.
Journal: Diabetes & vascular disease research 20110401
Title: [Incretin therapy and the metabolic syndrome].
Journal: Vnitrni lekarstvi 20110401
Title: Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.
Journal: The Medical letter on drugs and therapeutics 20110321
Title: Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20110301
Title: Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20110301
Title: Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
Journal: Diabetes care 20110201
Title: Alogliptin for the treatment of type 2 diabetes.
Journal: Drugs of today (Barcelona, Spain : 1998) 20110201
Title: Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Journal: Hospital practice (1995) 20110201
Title: Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Journal: Prescrire international 20110201
Title: Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Journal: Journal of medicinal chemistry 20110127
Title: Weight considerations in pharmacotherapy for type 2 diabetes.
Journal: Journal of obesity 20110101
Title: Understanding diabetes in patients with HIV/AIDS.
Journal: Diabetology & metabolic syndrome 20110101
Title: Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Journal: Postgraduate medicine 20110101
Title: Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.
Journal: Journal of medical case reports 20110101
Title: Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.
Journal: BMC endocrine disorders 20110101
Title: Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.
Journal: Journal of atherosclerosis and thrombosis 20110101
Title: Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.
Journal: PloS one 20110101
Title: Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.
Journal: Indian journal of endocrinology and metabolism 20110101
Title: From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.
Journal: Experimental diabetes research 20110101
Title: Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.
Journal: Journal of nutrition and metabolism 20110101
Title: Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20110101
Title: Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
Journal: Clinical drug investigation 20110101
Title: Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
Journal: Cardiovascular diabetology 20110101
Title: Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Journal: The open medicinal chemistry journal 20110101
Title: Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.
Journal: Journal of pharmacology & pharmacotherapeutics 20110101
Title: South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.
Journal: Indian journal of endocrinology and metabolism 20110101
Title: Choosing a gliptin.
Journal: Indian journal of endocrinology and metabolism 20110101
Title: Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
Journal: Open medicine : a peer-reviewed, independent, open-access journal 20110101
Title: Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Journal: PloS one 20110101
Title: Management of diabetes across the course of disease: minimizing obesity-associated complications.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20110101
Title: Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.
Journal: Clinical pharmacology : advances and applications 20110101
Title: [Treatment of diabetes mellitus in dialysis patients].
Journal: Terapevticheskii arkhiv 20110101
Title: Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
Journal: Clinical medicine insights. Endocrinology and diabetes 20110101
Title: Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.
Journal: Mayo Clinic proceedings 20101201
Title: 1-Adamantylmethyl 2-amino-benzoate.
Journal: Acta crystallographica. Section E, Structure reports online 20101201
Title: Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201
Title: DPP-4 inhibitors: what may be the clinical differentiators?
Journal: Diabetes research and clinical practice 20101101
Title: Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Journal: International journal of clinical practice 20101101
Title: Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.
Journal: Journal of clinical pharmacology 20101001
Title: SLCO1B1 polymorphism and oral antidiabetic drugs.
Journal: Basic & clinical pharmacology & toxicology 20101001
Title: Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
Journal: Expert opinion on drug metabolism & toxicology 20101001
Title: Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.
Journal: Current medical research and opinion 20101001
Title: Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Journal: Diabetes/metabolism research and reviews 20101001
Title: Liraglutide: effects beyond glycaemic control in diabetes treatment.
Journal: International journal of clinical practice. Supplement 20101001
Title: Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
Journal: The American journal of geriatric pharmacotherapy 20101001
Title: Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100915
Title: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Journal: Clinical pharmacokinetics 20100901
Title: Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Patient education and self-management.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Introduction.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Journal: The Journal of family practice 20100901
Title: [Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes].
Journal: Revue medicale de Liege 20100901
Title: [Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].
Journal: Medicina clinica 20100901
Title: Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Journal: The American journal of the medical sciences 20100801
Title: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Journal: Diabetes, obesity & metabolism 20100801
Title: Saxagliptin efficacy.
Journal: Diabetes, obesity & metabolism 20100801
Title: Recommendations for management of diabetes during Ramadan: update 2010.
Journal: Diabetes care 20100801
Title: Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Journal: The American journal of managed care 20100801
Title: Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals.
Journal: Indian journal of pharmacology 20100801
Title: The evolving place of incretin-based therapies in type 2 diabetes.
Journal: Pediatric nephrology (Berlin, Germany) 20100701
Title: Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.
Journal: Diabetes 20100701
Title: Saxagliptin: a new drug for the treatment of type 2 diabetes.
Journal: Mini reviews in medicinal chemistry 20100701
Title: GIP: an inconsequential incretin or not?
Journal: Diabetes care 20100701
Title: Incretin physiology and its role in type 2 diabetes mellitus.
Journal: The Journal of the American Osteopathic Association 20100701
Title: (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
Journal: Bioorganic & medicinal chemistry letters 20100615
Title: Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Journal: The Annals of pharmacotherapy 20100601
Title: Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
Journal: Pharmacotherapy 20100601
Title: Diabesity: therapeutic options.
Journal: Diabetes, obesity & metabolism 20100601
Title: Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Journal: Pharmacotherapy 20100501
Title: Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.
Journal: Diabetes, obesity & metabolism 20100501
Title: Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.
Journal: Diabetes, obesity & metabolism 20100501
Title: A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Journal: Postgraduate medicine 20100501
Title: Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
Journal: Postgraduate medicine 20100501
Title: Choosing among the incretin agents and why it matters.
Journal: The Journal of family practice 20100501
Title: [New hypoglycemic agents in type 2 diabetes].
Journal: La Revue du praticien 20100420
Title: Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Journal: Diabetes 20100401
Title: [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Journal: Pharmazie in unserer Zeit 20100301
Title: The physiologic role of incretin hormones: clinical applications.
Journal: The Journal of the American Osteopathic Association 20100301
Title: Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Journal: ChemMedChem 20100201
Title: Incretin concepts.
Journal: Diabetes care 20100201
Title: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.
Journal: Diabetes care 20100201
Title: Saxagliptin in type 2 diabetes.
Journal: Drugs of today (Barcelona, Spain : 1998) 20100201
Title: The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
Journal: Diabetes technology & therapeutics 20100101
Title: Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
Journal: Postgraduate medicine 20100101
Title: Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus.
Journal: Vascular health and risk management 20100101
Title: Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Journal: Vascular health and risk management 20100101
Title: Rhinorrhea, cough and fatigue in patients taking sitagliptin.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20100101
Title: Forecasting drug utilization and expenditure in a metropolitan health region.
Journal: BMC health services research 20100101
Title: Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.
Journal: Therapeutics and clinical risk management 20100101
Title: Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Journal: Cardiology in review 20100101
Title: Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
Journal: Vascular health and risk management 20100101
Title: Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors.
Journal: Cardiovascular diabetology 20100101
Title: Exenatide once weekly: clinical outcomes and patient satisfaction.
Journal: Patient preference and adherence 20100101
Title: Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Journal: Vascular health and risk management 20100101
Title: Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.
Journal: Core evidence 20100101
Title: The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session.
Journal: Diabetology & metabolic syndrome 20100101
Title: [The incretin effect and type 2 diabetes].
Journal: Revista medica del Instituto Mexicano del Seguro Social 20100101
Title: Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Title: Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Title: New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Title: Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Title: Saxagliptin for type 2 diabetes.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Title: Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
Journal: Drug, healthcare and patient safety 20100101
Title: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
Journal: The Journal of clinical endocrinology and metabolism 20091201
Title: Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Journal: Expert opinion on pharmacotherapy 20091201
Title: The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
Journal: Pharmacotherapy 20091201
Title: Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Journal: Cleveland Clinic journal of medicine 20091201
Title: Saxagliptin (Onglyza) for type 2 diabetes.
Journal: The Medical letter on drugs and therapeutics 20091102
Title: Incretin-based therapies: viewpoints on the way to consensus.
Journal: Diabetes care 20091101
Title: DPP-4 inhibitors in clinical practice.
Journal: Postgraduate medicine 20091101
Title: Saxagliptin.
Journal: Drugs 20091022
Title: Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
Journal: Current medical research and opinion 20091001
Title: Pharmacotherapy of hyperglycemia.
Journal: Expert opinion on pharmacotherapy 20091001
Title: Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.
Journal: Journal of managed care pharmacy : JMCP 20091001
Title: Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Journal: Clinical science (London, England : 1979) 20090928
Title: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Journal: Diabetes care 20090901
Title: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.
Journal: International journal of clinical practice 20090901
Title: FDA approves saxagliptin for type 2 diabetes.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090901
Title: Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Journal: Postgraduate medicine 20090901
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090901
Title: Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
Journal: European journal of medicinal chemistry 20090801
Title: Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20090801
Title: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Journal: Best practice & research. Clinical endocrinology & metabolism 20090801
Title: Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20090601
Title: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Journal: Diabetes, obesity & metabolism 20090601
Title: Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Journal: Advances in therapy 20090501
Title: Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry 20090301
Title: Diabetes treatment.
Journal: Diabetes care 20090301
Title: DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Journal: Advances in therapy 20090301
Title: Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: Advances in therapy 20090301
Title: Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
Journal: Current drug targets 20090101
Title: A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
Journal: Cardiovascular diabetology 20090101
Title: Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.
Journal: Therapeutics and clinical risk management 20090101
Title: New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
Journal: The Diabetes educator 20090101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20090101
Title: Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Journal: Journal of the American Pharmacists Association : JAPhA 20090101
Title: Efficacy and safety of incretin based therapies: clinical trial data.
Journal: Journal of the American Pharmacists Association : JAPhA 20090101
Title: Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
Journal: Pharmacological reports : PR 20090101
Title: Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride.
Journal: Journal of the American Pharmacists Association : JAPhA 20090101
Title: Alogliptin: a new addition to the class of DPP-4 inhibitors.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy 20090101
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Journal: Diabetes care 20081201
Title: Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Journal: Expert opinion on emerging drugs 20081201
Title: Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Journal: IDrugs : the investigational drugs journal 20081201
Title: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
Journal: Vascular health and risk management 20080801
Title: Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.
Journal: Core evidence 20080601
Title: Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20080501
Title: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Journal: The Journal of pharmacology and experimental therapeutics 20080401
Title: Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Journal: Vascular health and risk management 20080401
Title: Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation.
Journal: Protein science : a publication of the Protein Society 20080201
Title: The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.
Journal: Indian journal of pharmacology 20080101
Title: Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.
Journal: Clinical medicine. Pathology 20080101
Title: Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20071201
Title: 11 Years of cyanopyrrolidines as DPP-IV inhibitors.
Journal: Current topics in medicinal chemistry 20070101
Title: Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.
Journal: Journal of endocrinological investigation 20070101
Title: DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Journal: International journal of clinical practice 20061101
Title: Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Journal: Journal of medicinal chemistry 20061019
Title: Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Journal: Minerva endocrinologica 20060601
Title: Biocatalytic ammonolysis of (5S)-4,5-dihydro-1H-pyrrole-1,5-dicarboxylic acid, 1-(1,1-dimethylethyl)-5-ethyl ester: preparation of an intermediate to the dipeptidyl peptidase IV inhibitor Saxagliptin.
Journal: Bioorganic & medicinal chemistry letters 20060201
Title: Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118).
Journal: Archives of biochemistry and biophysics 20060101
Title: Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Journal: Journal of medicinal chemistry 20050728
Title: Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.
Journal: Treatments in endocrinology 20050101
